Atreca, Inc., a Redwood City, Calif.-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, closed a $125m Series C financing.
The round was led by an existing investor, which is un unnamed U.S.-based, healthcare-focused fund, with participation from existing investors Wellington Management Company, and Cormorant Asset Management, and new investors Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital, and funds managed by Tekla Capital Management.
The company intends to use the funds to broaden and accelerate its discovery and pipeline generation efforts and to move its first candidate into clinical development.
Led by John A. Orwin, President and CEO, Atreca is a biotechnology company developing novel therapeutics based on a deep understanding of the human immune response of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes.
The company Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications.